—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Krystal Biotech Inc (KRYS) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for KRYS, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sector × region Health care in US: +1.8% week · −1.3% month · +6.9% quarter · +12.8% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-26
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 1.11 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How KRYS has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.11 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Krystal Biotech Inc moved 1.11% on average · correlation 0.27 · higher than 90% of US names
  • Beta, last 3 months 1.16 about the same as over the year
  • On the 10 worst bond days −1.72% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.94% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against KRYS on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Krystal Biotech Inc

KRYS in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Krystal Biotech is a commercial-stage biotechnology company that develops and sells genetic medicines for diseases with few existing treatments. Its approved product, VYJUVEK, treats a rare skin disorder called dystrophic epidermolysis bullosa. The company also runs a pipeline of experimental gene-based therapies for conditions such as cystic fibrosis, ocular disease and certain skin conditions. Founded in 2016, it is headquartered in Pittsburgh, Pennsylvania.
Where it sits in the stack
Krystal Biotech holds no seat in Rubin or Halo, our indices for the AI build-out; it sits outside that stack entirely, in the healthcare and biotechnology sleeve of the wider universe the diary follows, as a maker of gene-based therapies rather than a supplier to compute infrastructure.
Who it is priced against
Closelooknet's peer group holds no comparison set for Krystal Biotech; the diary notes the market sometimes compares it with Ultragenyx Pharmaceutical, another gene-therapy focused biotech.
Why Closelooknet tracks it
Krystal Biotech holds no seat in Rubin or Halo and has not appeared in any of our editions to date. It carries a Closelooknet score, but with only one module scored so far, the score is still being built.
What the diary watches
The diary watches how sales of VYJUVEK develop and whether pipeline programmes such as those for cystic fibrosis and ocular disease progress through further trials.

Krystal Biotech Inc (KRYS) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 61/100 composite (momentum 68, quality 85, valuation 19) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Goldman Sachs, 2026-09-24

The Street on this name

Analyst actions and the latest print for KRYS from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Goldman Sachs — target 441 Target set to $441 (+29% to spot) 2026-09-24

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What KRYS pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +0.7% in FY2025 55 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Krystal Biotech Inc (KRYS)?

Krystal Biotech Inc trades as KRYS on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is KRYS in a Closelooknet index?

Not currently — Krystal Biotech Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

What is Krystal Biotech Inc's Closelooknet composite score?

61 out of 100, with momentum 68, quality 85 and valuation 19 sub-scores, as of 2026-09-26. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does KRYS trade against its moving averages?

Uptrend stack intact: Trades +0.7% vs the 50-day and +15.6% vs the 200-day average, 9.6% below the 52-week high and +118.8% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Krystal Biotech Inc trade when bond yields rise?

Over the past year Krystal Biotech Inc had a beta of 1.11 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 90% of US names. On the 10 sessions in which long bonds fell most it moved −1.72% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Krystal Biotech Inc do?

Krystal Biotech is a commercial-stage biotechnology company that develops and sells genetic medicines for diseases with few existing treatments. Its approved product, VYJUVEK, treats a rare skin disorder called dystrophic epidermolysis bullosa. The company also runs a pipeline of experimental gene-based therapies for conditions such as cystic fibrosis, ocular disease and certain skin conditions. Closelooknet's peer group holds no comparison set for Krystal Biotech; the diary notes the market sometimes compares it with Ultragenyx Pharmaceutical, another gene-therapy focused biotech.

Where does Krystal Biotech Inc sit in the AI build-out?

Krystal Biotech holds no seat in Rubin or Halo, our indices for the AI build-out; it sits outside that stack entirely, in the healthcare and biotechnology sleeve of the wider universe the diary follows, as a maker of gene-based therapies rather than a supplier to compute infrastructure. Krystal Biotech holds no seat in Rubin or Halo and has not appeared in any of our editions to date. It carries a Closelooknet score, but with only one module scored so far, the score is still being built.

Does Krystal Biotech Inc pay a dividend?

No cash distribution shows in Krystal Biotech Inc’s price series over the last three years. The share count rose 0.7% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Krystal Biotech Inc recently?

The most recent analyst action on Krystal Biotech Inc on the Closelooknet wire is a price target by Goldman Sachs on 2026-09-24 (target 441). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for KRYS, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.